DxVx to license OVM-200 anti-cancer vaccine candidate, hold trials in Asia
The therapeutic vaccine candidate is currently slated to enter into a Phase 1b trial following the completion of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Nov 23
The therapeutic vaccine candidate is currently slated to enter into a Phase 1b trial following the completion of…
Patient CarePharmaceuticals and MedicinesPartnerships and Licensing Agreements
27 Nov 23
Sebelipase alfa is an enzyme replacement therapy, which works by replacing an enzyme missing in the body, alongside…
24 Nov 23
The commission has approved Kaftrio in combination with ivacaftor to treat CF in patients aged two years and…
24 Nov 23
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
24 Nov 23
This milestone follows the approval granted by the Drug Controller General of India for the Dry Powder Inhaler…
23 Nov 23
Boehringer Ingelheim said its immune-modulatory cancer medicines will benefit from T3 Pharma's advanced technology, supporting the company's oncology…
23 Nov 23
This marks a significant milestone as XEOMIN is the first approved neurotoxin for the treatment of this condition…
22 Nov 23
As a result of the settlement, Fresenius Medical Care has projected a net positive impact on operating income…
21 Nov 23
In the complaint, filed in Harrison County, Texas District Court, Paxton accused Pfizer and Tris Pharma of manipulating…
21 Nov 23
Zevra aims to advance in the development and commercialisation of treatments for rare diseases and support patient communities…